Opus Genetics, Inc.
Opus Genetics, Inc. (IRD): 3 pipeline candidates · ~15 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.6 months
D/E -1.92 · 22% dilution
Lead: Phase 1/Phase 2
3 candidates
N/A
2 buys · 11 sells (180d)
A transparent, data-derived signal for Opus Genetics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$320.8M
Cash
$60.0M
Quarterly Burn
$12.7M
Runway
14.6 mo
Revenue
$2.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| aav8.hlca5 | Phase 1/Phase 2 |
| opgx-best1 | Phase 1/Phase 2 |
| opgx-lca5 | — |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$216.7M
| Holder | Shares | Value |
|---|---|---|
| caligan partners lp | 6,075,028 | $27.6M |
| adage capital partners gp, l.l.c. | 6,029,775 | $27.4M |
| vanguard capital management llc | 4,899,974 | $22.3M |
| bios capital management, lp | 3,683,429 | $16.8M |
| perceptive advisors llc | 3,671,684 | $16.7M |
| balyasny asset management l.p. | 2,718,029 | $12.4M |
| woodline partners lp | 2,708,060 | $12.3M |
| millennium management llc | 2,630,432 | $12.0M |
| marshall wace, llp | 2,313,380 | $10.5M |
| adar1 capital management, llc | 1,849,004 | $8.4M |
Showing top 10 of 77 institutional holders of Opus Genetics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Opus Genetics, Inc.'s pipeline?
Opus Genetics, Inc. (IRD) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Opus Genetics, Inc.'s lead drug candidate?
Opus Genetics, Inc.'s most advanced tracked candidate is aav8.hlca5 (Phase 1/Phase 2) for LCA5.
What is Opus Genetics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Opus Genetics, Inc. has approximately 14.6 months of cash runway.
What is Opus Genetics, Inc.'s market capitalization?
Opus Genetics, Inc.'s market capitalization is approximately $320.8M.
Who is the CEO of Opus Genetics, Inc.?
Dr. George Magrath M.B.A., M.D., M.S. is the chief executive officer of Opus Genetics, Inc. (IRD).
Get the full picture on Opus Genetics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.